Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioMarin PharmaceuticalMEX:BMRN 80 3-Year ROIIC % is 30.54 as of Dec. 2025, which is 46% above its 10-year median of 20.92. GuruFocus rates MEX:BMRN with a GF Score™ of 80/100 and a GF Value™ of MXN1,507.35 (Significantly Undervalued). The stock has 3 warning signs investors should review. Among 1,322 Biotechnology companies, BioMarin Pharmaceutical ranks better than 68.46% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
BioMarin Pharmaceutical's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 30.54%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for BioMarin Pharmaceutical's 3-Year ROIIC % or its related term are showing as below:
MEX:BMRN's 3-Year ROIIC % is ranked better than 68.46% of 1322
companies
in the Biotechnology industry
Industry Median: -4.9
vs MEX:BMRN: 30.54
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
BioMarin Pharmaceutical 3-Year ROIIC % Related Terms
BioMarin Pharmaceutical 3-Year ROIIC % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:BMRN vs CYTK, ARWR, TECH: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, BioMarin Pharmaceutical's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioMarin Pharmaceutical 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioMarin Pharmaceutical's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where BioMarin Pharmaceutical's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
BioMarin Pharmaceutical (MEX:BMRN) has a 3-Year ROIIC % of 30.54 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on BioMarin Pharmaceutical and its competitors. This is 46% above median its historical median of 20.92. Over the past decade, BioMarin Pharmaceutical's 3-Year ROIIC % has ranged from 1.25 to 89.20. According to the industry distribution chart, BioMarin Pharmaceutical ranks #417 out of 1322 companies in the Biotechnology industry, placing it in the top 31.5%.
Is BioMarin Pharmaceutical's 3-Year ROIIC % too high?
BioMarin Pharmaceutical's current 3-Year ROIIC % of 30.54 is 46% above median its 10-year median of 20.92. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 89.20. Based on the distribution chart, BioMarin Pharmaceutical ranks #417 out of 1322 companies in the Biotechnology industry, which is above the industry midpoint. Overall, BioMarin Pharmaceutical has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BioMarin Pharmaceutical's 3-Year ROIIC % compare to CYTK and ARWR?
According to the Biotechnology industry distribution chart, BioMarin Pharmaceutical ranks #417 out of 1322 companies for 3-Year ROIIC %. This puts BioMarin Pharmaceutical in the upper half of its industry. Historically, BioMarin Pharmaceutical's own 3-Year ROIIC % has ranged from 1.25 to 89.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on BioMarin Pharmaceutical and its competitors. BioMarin Pharmaceutical's current 3-Year ROIIC % is 30.54, which is 46% above median its own 10-year median of 20.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioMarin Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, BioMarin Pharmaceutical (MEX:BMRN) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN1,507.35, compared to a current price of MXN959.00 — trading 36.4% below its estimated fair value. The current 3-Year ROIIC % is 30.54, which is 46% above median its 10-year median of 20.92. BioMarin Pharmaceutical's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For BioMarin Pharmaceutical (MEX:BMRN), the current 3-Year ROIIC % is 30.54 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioMarin Pharmaceutical (MEX:BMRN) Overvalued in 2026?
Based on GuruFocus' analysis, BioMarin Pharmaceutical stock appears to be undervalued.
The current stock price of MXN959.00 is trading 36.4% below its estimated GF Value™ of MXN1,507.35.
GuruFocus considers BioMarin Pharmaceutical to be Significantly Undervalued.
Key valuation signals for MEX:BMRN:
3-Year ROIIC %: 30.54 (46% above median its 10-year median of 20.92)
GF Value™: MXN1,507.35 vs. price of MXN959.00 (36.4% below fair value)
No single metric tells the full story. See the MEX:BMRN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
80GF Score
Get the complete analysis for MEX:BMRN
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:BMRN has been successfully added to your 
